OMER Key Statistics, Chart & Performance
The current stock price of OMER is 14.09 USD. In the past month the price increased by 23.6%. In the past year, price increased by 59.39%.
OMER Latest News, Press Relases and Analysis
OMER Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 50.39 | 1.05T | ||
| JNJ | JOHNSON & JOHNSON | 19.99 | 499.91B | ||
| MRK | MERCK & CO. INC. | 12.33 | 269.55B | ||
| PFE | PFIZER INC | 7.9 | 143.73B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 8.65 | 115.47B | ||
| ZTS | ZOETIS INC | 19.82 | 55.38B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 10.07 | 23.89B | ||
| VTRS | VIATRIS INC | 5.35 | 14.35B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 23.79 | 11.35B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 8.60B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 5.73B | ||
| CRNX | CRINETICS PHARMACEUTICALS IN | N/A | 5.06B |
Related stock screener links
About OMER
Company Profile
Omeros Corp. operates as a biopharmaceutical company. The company is headquartered in Seattle, Washington and currently employs 202 full-time employees. The company went IPO on 2009-10-08. The firm is focused on discovering, developing, and commercializing first-in-class small-molecule and protein therapeutics for both large-market and orphan diseases, with a particular emphasis on complement-mediated diseases, cancers, and addictive or compulsive disorders. The firm's lead MASP-2 inhibitor, narsoplimab, targets the lectin pathway of complement and is the subject of a biologics license application pending before the FDA for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy. Its long-acting MASP-2 inhibitor, OMS1029, is in phase I single- and multiple-ascending-dose clinical studies. Its lead phosphodiesterase 7 (PDE7) inhibitor, OMS527, is in clinical development for the treatment of cocaine use disorders. The firm also has preclinical programs, including an oncology platform for the development of novel therapeutics.
Company Info
OMEROS CORP
201 Elliott Avenue West
Seattle WASHINGTON 98119 US
CEO: Gregory A. Demopulos
Employees: 202
Phone: 12066765000
OMEROS CORP / OMER FAQ
What does OMEROS CORP do?
Omeros Corp. operates as a biopharmaceutical company. The company is headquartered in Seattle, Washington and currently employs 202 full-time employees. The company went IPO on 2009-10-08. The firm is focused on discovering, developing, and commercializing first-in-class small-molecule and protein therapeutics for both large-market and orphan diseases, with a particular emphasis on complement-mediated diseases, cancers, and addictive or compulsive disorders. The firm's lead MASP-2 inhibitor, narsoplimab, targets the lectin pathway of complement and is the subject of a biologics license application pending before the FDA for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy. Its long-acting MASP-2 inhibitor, OMS1029, is in phase I single- and multiple-ascending-dose clinical studies. Its lead phosphodiesterase 7 (PDE7) inhibitor, OMS527, is in clinical development for the treatment of cocaine use disorders. The firm also has preclinical programs, including an oncology platform for the development of novel therapeutics.
What is the stock price of OMEROS CORP today?
The current stock price of OMER is 14.09 USD. The price increased by 4.14% in the last trading session.
What is the dividend status of OMEROS CORP?
OMER does not pay a dividend.
What is the ChartMill technical and fundamental rating of OMER stock?
OMER has a ChartMill Technical rating of 9 out of 10 and a ChartMill Fundamental rating of 0 out of 10.
Can you provide the PE ratio for OMER stock?
OMEROS CORP (OMER) does not have a PE ratio as the earnings reported over the last twelve months were negative (-2.02).
What is the market capitalization of OMER stock?
OMEROS CORP (OMER) has a market capitalization of 998.98M USD. This makes OMER a Small Cap stock.
OMER Technical Analysis
ChartMill assigns a technical rating of 9 / 10 to OMER. When comparing the yearly performance of all stocks, OMER is one of the better performing stocks in the market, outperforming 98.55% of all stocks.
OMER Financial Highlights
Over the last trailing twelve months OMER reported a non-GAAP Earnings per Share(EPS) of -2.02. The EPS increased by 12.55% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -65.24% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
OMER Forecast & Estimates
11 analysts have analysed OMER and the average price target is 34.34 USD. This implies a price increase of 143.72% is expected in the next year compared to the current price of 14.09.